JP2022511096A5 - - Google Patents
Info
- Publication number
- JP2022511096A5 JP2022511096A5 JP2021532209A JP2021532209A JP2022511096A5 JP 2022511096 A5 JP2022511096 A5 JP 2022511096A5 JP 2021532209 A JP2021532209 A JP 2021532209A JP 2021532209 A JP2021532209 A JP 2021532209A JP 2022511096 A5 JP2022511096 A5 JP 2022511096A5
- Authority
- JP
- Japan
- Prior art keywords
- present
- antibody
- cancer
- caf
- therapy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862777101P | 2018-12-08 | 2018-12-08 | |
| US62/777,101 | 2018-12-08 | ||
| PCT/US2019/065008 WO2020118216A1 (en) | 2018-12-08 | 2019-12-06 | Identification and targeting of tumor promoting carcinoma associated fibroblasts for diagnosis and treatment of cancer and other diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022511096A JP2022511096A (ja) | 2022-01-28 |
| JP2022511096A5 true JP2022511096A5 (https=) | 2024-03-05 |
Family
ID=70973537
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021532209A Pending JP2022511096A (ja) | 2018-12-08 | 2019-12-06 | がんおよび他の疾患の診断および処置のための腫瘍促進がん関連線維芽細胞の同定および標的化 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20220144938A1 (https=) |
| EP (1) | EP3890802A4 (https=) |
| JP (1) | JP2022511096A (https=) |
| KR (1) | KR20210102331A (https=) |
| CN (1) | CN113412130A (https=) |
| AU (1) | AU2019392915B2 (https=) |
| CA (1) | CA3121933A1 (https=) |
| WO (1) | WO2020118216A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3775258A4 (en) | 2018-03-28 | 2022-01-26 | Board of Regents, The University of Texas System | IDENTIFICATION OF EPIGENETIC ALTERATIONS IN DNA ISOLATED FROM EXOSOMES |
| WO2021158966A1 (en) | 2020-02-05 | 2021-08-12 | Board Of Regents, The University Of Texas System | Diagnostic and prognostic utility of exosomes in immunotherapy |
| EP4405379A4 (en) * | 2021-09-24 | 2025-08-20 | Synergy Imt Inc | COMPOSITION OF RECOMBINANT ANTIGEN-BINDING MOLECULES AND METHOD OF MANUFACTURE AND USE THEREOF |
| CN114529541A (zh) * | 2022-03-28 | 2022-05-24 | 中国人民解放军海军军医大学第一附属医院 | 预测胰腺癌微环境中细胞表达的方法、电子设备、介质及系统 |
| CN114533884A (zh) * | 2022-04-20 | 2022-05-27 | 澳门大学 | 一种联合治疗癌症的药物及s100a9-cxcl12信号抑制剂的应用 |
| WO2025242065A1 (zh) * | 2024-05-23 | 2025-11-27 | 苏州易慕峰生物科技有限公司 | 一种预测实体瘤免疫细胞疗法治疗应答的方法 |
| CN119570741A (zh) * | 2024-12-20 | 2025-03-07 | 江苏亲科生物研究中心有限公司 | 一种wdr89单克隆抗体及其试剂盒的制备方法和用途 |
| CN119735640A (zh) * | 2024-12-23 | 2025-04-01 | 中国人民解放军空军军医大学 | Ms4a6c抗原表位肽、抗原、抗体、杂交瘤细胞株及用途 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2769737T (pt) * | 2009-07-20 | 2017-06-29 | Bristol Myers Squibb Co | Combinação de um anticorpo anti-ctla4 com etopósido para o tratamento sinérgico de doenças proliferativas |
| WO2011149046A1 (ja) * | 2010-05-28 | 2011-12-01 | 独立行政法人国立がん研究センター | 膵癌治療剤 |
| WO2016145030A1 (en) * | 2015-03-11 | 2016-09-15 | Providence Health & Services-Oregon | Compositions and methods for enhancing the efficacy of cancer therapy |
| WO2017040686A1 (en) * | 2015-09-01 | 2017-03-09 | University Of Miami | Identification of circulating cancer associated fibroblasts |
| TWI910495B (zh) * | 2016-05-13 | 2026-01-01 | 美商再生元醫藥公司 | 藉由投予pd-1抑制劑治療皮膚癌之方法 |
| SG11201900344YA (en) * | 2016-07-15 | 2019-02-27 | Novartis Ag | Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor |
-
2019
- 2019-12-06 EP EP19891878.1A patent/EP3890802A4/en active Pending
- 2019-12-06 WO PCT/US2019/065008 patent/WO2020118216A1/en not_active Ceased
- 2019-12-06 CN CN201980091486.5A patent/CN113412130A/zh active Pending
- 2019-12-06 AU AU2019392915A patent/AU2019392915B2/en active Active
- 2019-12-06 KR KR1020217021272A patent/KR20210102331A/ko active Pending
- 2019-12-06 US US17/299,265 patent/US20220144938A1/en not_active Abandoned
- 2019-12-06 JP JP2021532209A patent/JP2022511096A/ja active Pending
- 2019-12-06 CA CA3121933A patent/CA3121933A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022511096A5 (https=) | ||
| AU2023237216A1 (en) | BCMA And CD3 Bispecific T Cell Engaging Antibody Constructs | |
| US20250368737A1 (en) | Low ph pharmaceutical composition comprising t cell engaging antibody constructs | |
| US12252546B2 (en) | Anti-SIRPa antibodies and their therapeutic applications | |
| KR102749049B1 (ko) | 분자를 표적화하기 위한 항원 결합 구조체 | |
| JP6682426B2 (ja) | 抗ｂ７−ｈ５抗体およびその使用 | |
| AU2018295119B2 (en) | Multi-specific antibodies and methods of making and using thereof | |
| EP3645742A2 (en) | Anti-ror1 antibodies and methods of making and using thereof | |
| NZ791623A (en) | Anti-CTLA4 and anti-PD-1 bifunctional antibody, pharmaceutical composition thereof and use thereof | |
| TW201803899A (zh) | 三特異性和／或三價結合蛋白 | |
| TW202221021A (zh) | 改良之抗原結合受體 | |
| TWI833244B (zh) | 一種雙抗組合及其應用 | |
| WO2021216468A1 (en) | Human tigit specific single domain antibodies and methods of use | |
| KR20210149141A (ko) | 삼중특이적 결합 단백질, 이의 방법 및 용도 | |
| JP2022534212A (ja) | 免疫チェックポイント阻害剤と組み合わせてｓｉｒｐアルファｆｃ融合によりがんを治療する方法 | |
| JP2024123004A (ja) | エキソソーム標的化二重特異性抗体 | |
| CN117279950B (zh) | 一种靶向il-18bp的抗体及其应用 | |
| CN119137147A (zh) | 具有增加的选择性的多链多靶向性双特异性抗原结合分子 | |
| TW202328196A (zh) | 使用vista抗原結合分子的癌症之治療及預防 | |
| WO2025061050A1 (en) | Antibodies targeting ctla4 and cd47 and uses thereof | |
| KR20230104229A (ko) | Cd3에 결합하는 폴리펩티드 구축물 | |
| EP4011918A1 (en) | Dual-specific protein | |
| CN121079322A (zh) | 抗cd27单克隆抗体及其应用 | |
| AU2024347003A1 (en) | Antibodies targeting ctla4 and cd47 and uses thereof | |
| WO2024193668A1 (zh) | 抗ctla-4/抗tigit双特异性抗体及其应用 |